1620675-81-1

Upstream product

• 1620675-51-5 (3R,6S)-1-benzyl 3-methyl 6-(hydroxymethyl)piperidine-1,3-dicarboxylate 

Downstream Products

• 1620677-01-1 (3R,6S)-1-benzyl 3-methyl 6-(2-hydroxypropan-2-yl)piperidine-1,3-dicarboxylate 
• 1620677-00-0 (3R,6S)-1-benzyl 3-methyl 6-acetylpiperidine-1,3-dicarboxylate 
• 1620675-47-9 4-{8-amino-3-[(6R,8aS)-1,1-dimethyl-3-oxohexahydro[1,3]oxazolo[3,4-a]pyridin-6-yl]imidazo[1,5-a]pyrazin-1-yl}-3-methoxy-N-[4-(trifluoromethyl)pyridin-2-yl]benzamide 
• 1620675-80-0 (3R,6S)-1-benzyl 3-methyl 6-(1-hydroxyethyl)piperidine-1,3-dicarboxylate 
• 1620674-09-0 4-{8-amino-3-[(1R,6R,8aS)-1-methyl-3-oxohexahydro[1,3]oxazolo[3,4-a]pyridin-6-yl]imidazo[1,5-a]pyrazin-1-yl}-3-methoxy-N-[4-(trifluoromethyl)pyridin-2-yl]benzamide 

Relevant academic research and scientific papers

BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, or pharmaceutically acceptable salts thereof, Formula I or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.